Last updated: 2026-10-13 21:57:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
ImmunityBio, Inc. (IBRX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $9.81, with a market capitalisation of $11.14B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.95 to $12.43. This page covers its latest market performance, valuation, price trends and company information.
$11.14B | |
$10.00 | |
$40.83 | |
$1.21 | |
$10.12 | |
10.36M | |
10.43M | |
-- | |
$12.43 | |
$1.95 | |
-- | |
-- |
ImmunityBio, Inc. (IBRX) is trading at $9.86 in after-hours trading as of 2026-10-13 21:52:00, down 2.53% ($0.26) from the regular-session close of $10.12.
After-hours trading shows how investors are pricing IBRX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, ImmunityBio, Inc. (IBRX) moved from $10.29 to $9.81, representing a decline of 4.58% ($0.47).
The stock traded between $9.33 and $10.81 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 16.71 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 75.0%
IBRX is currently trading at $9.81, placing it 75.0% of the way from its 52-week low of $1.95 to its 52-week high of $12.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 691 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ImmunityBio, Inc. (IBRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.